ASX:4DXHealthcare Services
How Investors May Respond To 4DMedical (ASX:4DX) Losses Surging Despite Flat Half-Year Revenue
In late February 2026, 4DMedical Limited reported half-year results to 31 December 2025, with sales of A$2.85 million, broadly unchanged from A$2.90 million a year earlier, but net loss widening sharply to A$154.14 million and basic loss per share reaching A$0.311.
The stark contrast between relatively stable revenue and a very large increase in losses highlights how cost structure and investment spending are weighing on profitability.
Next, we'll examine how this sharp widening in net loss...